Evidence map›Paper›PMID 30734019›Full record

ArticleBJS open2019

Population-based study of the impact of surgical and adjuvant therapy at the same or a different institution on survival of patients with pancreatic adenocarcinoma.

N Latchana, L Davis, N G Coburn, A Mahar, Y Liu, A Hammad, D Kagedan, M Elmi, M Siddiqui, C C Earle and 1 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in BJS open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Building of CuOPharmaceutics · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Geographic impact on access to care and survival for non-curative esophagogastric cancer: a population-based study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2021
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 2 countries.

N LatchanaDepartment of Surgery, University of Toronto, Toronto, Ontario, Canada.
L DavisSunnybrook Research Institute, Toronto, Ontario, Canada.
N G CoburnDepartment of Surgery, University of Toronto, Toronto, Ontario, Canada.
A MaharDepartment of Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
Y LiuInstitute of Clinical Evaluative Sciences, Toronto, Ontario, Canada.
A HammadSunnybrook Research Institute, Toronto, Ontario, Canada.
D KagedanDepartment of Surgery, University of Toronto, Toronto, Ontario, Canada.
M ElmiDepartment of Surgery, University of Toronto, Toronto, Ontario, Canada.
M SiddiquiSunnybrook Research Institute, Toronto, Ontario, Canada.
C C EarleDepartment of Medicine, University of Toronto, Toronto, Ontario, Canada.
J HalletDepartment of Surgery, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-5108-1072
Sunnybrook Health Science Centre · CASunnybrook Hospital · CAUniversity of Toronto · CAInstitute for Clinical Evaluative Sciences · CAMansoura University · EGOntario Institute for Cancer Research · CAUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Pancreatic cancer surgery is increasingly regionalized in high-volume centres. Provision of adjuvant chemotherapy in the same institution can place a burden on patients, whereas receiving adjuvant chemotherapy at a different institution closer to home may create disparities in care. This study compared long-term outcomes of patients with pancreatic adenocarcinoma receiving adjuvant chemotherapy at the institution where they had undergone surgery with outcomes for those receiving chemotherapy at a different institution. Methods: This was a population-based study of patients receiving adjuvant chemotherapy after resection of pancreatic adenocarcinoma performed at ten designated hepatopancreatobiliary centres in Ontario, Canada, between 2004 and 2014. Patients were divided into those receiving chemotherapy at the same institution as surgery or a different institution from where surgery was performed. The primary outcome was overall survival (OS). Multivariable Cox regression assessed the association between OS and each chemotherapy group, adjusted for potential confounders. Results: Of 589 patients, 374 Conclusion: After pancreatectomy for pancreatic adenocarcinoma at specialized hepatopancreatobiliary surgery centres, OS was not affected by the location of the centre delivering adjuvant chemotherapy. Receiving this treatment in a local centre reduced patients' travel burden.

Indexed as

PancreatectomyPatient TransferAdenocarcinomaAgedAntineoplastic AgentsChemotherapy, AdjuvantFemaleHealth Services AccessibilityHumansMaleMiddle AgedOncology Service, HospitalOntarioPancreatic NeoplasmsRegistriesSocial ClassAntineoplastic Agents

Identifiers

PMID30734019
PMCPMC6354229
OpenAlexW2903143762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.